<DOC>
	<DOCNO>NCT01675622</DOCNO>
	<brief_summary>The efficacy dose titration OxyNorm™ immediate-release capsule versus morphine immediate-release tablet treatment cancer pain .</brief_summary>
	<brief_title>Immediate-Release Oxycodone Capsules Study Cancer Pain</brief_title>
	<detailed_description>To compare efficacy dose titration OxyNorm™ immediate-release capsule versus morphine immediate-release tablet treatment cancer pain .</detailed_description>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>1 . Patients either sex age 18 80 year inclusive , cancer type . 2 . Patients moderate severe cancer pain , whose pain intensity NRS ≥4 . 3 . Patients understand able complete NRS BPI assessment . 4 . Patients give write informed consent participate study . 1 . Patients pregnant , lactate . 2 . Patients unable manage pain effectively opioids . 3 . Patient need ≥120mg morphine equivalent treatment pain time study entry ; 4 . Patients receive chemotherapy , still responsive period chemotherapy ( patient interval period chemotherapy enrol study . That say , patient complete chemotherapy 2 week enrol , patient complete chemotherapy least one week could enrol discretion investigator ) . 5 . Patients receive radiotherapy bony metastasis , patient receive radiotherapy within 4 week period study entry ( patient receive radiotherapy area pain area enrol ) , patient schedule receive radiotherapy pain area study period . 6 . Patients receive receive anticonvulsion drugs/anti depression drug consider investigator treatment neuropathy pain . Patients receive receive analgesic study medicine , include NSAIDs . 7 . Patients unstable disease , dysfunction important organ . 8 . Patients ongoing infection , abscess fever . 9 . Patient serious abnormal liver/ renal function ( ALT/AST/creatinine/urea nitrogen ) high 3 time upper limit ; 10 . Paralytic mechanical ileus ; 11 . Persistent asthma , chronic obstructive disease , cor pulmonary ; 12 . Intracranial neoplasm , intracranial hypertension central respiratory depression risk . 13 . Monoamine oxidase inhibitor ( MAOIs ) type drug administer last 2 week ; 14 . Patients currently take active treatment epilepsy arrhythmia . 15 . Patients known sensitivity record specific allergic reaction oxycodone morphine . 16 . Patients exclude contraindication , adverse drug reaction ( ADRs ) drug interaction oxycodone morphine detail data sheet , summary product characteristic investigator 's brochure . 17 . Patients history drug alcohol abuse . 18 . Patients participate another clinical research study involve new chemical entity within one month prior study entry . 19 . Patients whose concomitant medication likely change within study period , exception treatment opioid side effect . 20 . Patients , opinion investigator , unsuitable participate study reason mention inclusion exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Cancer Pain</keyword>
</DOC>